MX393076B - Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ - Google Patents
Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+Info
- Publication number
- MX393076B MX393076B MX2018012849A MX2018012849A MX393076B MX 393076 B MX393076 B MX 393076B MX 2018012849 A MX2018012849 A MX 2018012849A MX 2018012849 A MX2018012849 A MX 2018012849A MX 393076 B MX393076 B MX 393076B
- Authority
- MX
- Mexico
- Prior art keywords
- derivatives
- riboside
- nicotinic acid
- nicotinamide
- ribofuranosyl
- Prior art date
Links
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 title abstract 3
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 title abstract 2
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract 2
- 239000011618 nicotinamide riboside Substances 0.000 title abstract 2
- 239000002243 precursor Substances 0.000 title 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 abstract 4
- IPXBSAHANXBVMU-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-2H-pyridine-3-carboxamide Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1CC(C(=O)N)=CC=C1)O IPXBSAHANXBVMU-OTVLKRCQSA-N 0.000 abstract 1
- QGZHUIXTGFZHJT-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4H-pyridine-3-carboxamide Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1C=C(C(=O)N)CC=C1)O QGZHUIXTGFZHJT-OTVLKRCQSA-N 0.000 abstract 1
- JJICLWRQGDROCF-OTVLKRCQSA-N 1-[(2R,3R,4R,5R)-3,4-diacetyl-3,4-dihydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4H-pyridine-3-carboxylic acid Chemical compound C(C)(=O)[C@@]1([C@@H](O[C@@H]([C@]1(O)C(C)=O)C(O)C(C)=O)N1C=C(C(=O)O)CC=C1)O JJICLWRQGDROCF-OTVLKRCQSA-N 0.000 abstract 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 abstract 1
- 235000013361 beverage Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000015872 dietary supplement Nutrition 0.000 abstract 1
- 230000037041 intracellular level Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229950006238 nadide Drugs 0.000 abstract 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325264P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028673 WO2017184885A1 (en) | 2016-04-20 | 2017-04-20 | Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012849A MX2018012849A (es) | 2019-08-29 |
| MX393076B true MX393076B (es) | 2025-03-24 |
Family
ID=60088650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012849A MX393076B (es) | 2016-04-20 | 2017-04-20 | Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10183036B2 (enExample) |
| EP (1) | EP3445359B8 (enExample) |
| JP (3) | JP7089480B2 (enExample) |
| KR (1) | KR20190008246A (enExample) |
| CN (1) | CN109640984A (enExample) |
| AU (2) | AU2017254657A1 (enExample) |
| BR (1) | BR112018071573A2 (enExample) |
| CA (1) | CA3021571C (enExample) |
| ES (1) | ES2948968T3 (enExample) |
| MX (1) | MX393076B (enExample) |
| NZ (1) | NZ747693A (enExample) |
| WO (1) | WO2017184885A1 (enExample) |
| ZA (1) | ZA201807736B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10392414B2 (en) | 2015-07-15 | 2019-08-27 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| EA035664B1 (ru) | 2015-08-05 | 2020-07-23 | МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи | Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+ |
| GB2542881B (en) | 2015-10-02 | 2020-01-01 | Carr Andrew | Crystal forms of ß-nicotinamide mononucleotide |
| NZ803738A (en) | 2016-11-11 | 2024-05-31 | Chromadex Inc | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof |
| MX2019006278A (es) | 2016-11-29 | 2019-08-21 | Univ Iowa Res Found | Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia. |
| US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
| WO2018191771A1 (en) * | 2017-04-18 | 2018-10-25 | Victor Chang Cardiac Research Institute | Detection and treatment of congenital malformations |
| SG11201912267SA (en) | 2017-06-19 | 2020-01-30 | Gangadhara Ganapati | Nicotinamide riboside derivatives and their uses |
| US11180521B2 (en) | 2018-01-30 | 2021-11-23 | Metro International Biotech, Llc | Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof |
| JP2021525279A (ja) * | 2018-05-22 | 2021-09-24 | ジャンプスタート ファーティリティ ピーティーワイ リミテッド | 抗加齢剤としてのニコチン酸リボシドのアミノ酸塩 |
| US11833167B2 (en) | 2018-12-17 | 2023-12-05 | Mitopower Llc | Nicotinyl riboside compounds and their uses |
| CN113727987A (zh) * | 2019-02-21 | 2021-11-30 | 可劳迈戴斯有限公司 | 烟酰胺核苷、烟酸核苷、还原型烟酰基核苷化合物和烟酰基核苷化合物衍生物在制品的用途 |
| US11939348B2 (en) | 2019-03-22 | 2024-03-26 | Metro International Biotech, Llc | Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide |
| CA3139615A1 (en) * | 2019-06-05 | 2020-12-10 | Societe Des Produits Nestle S.A. | Reduced nicotinamideribosides for the treatment/prevention of liver disease |
| CN113784720A (zh) * | 2019-06-05 | 2021-12-10 | 雀巢产品有限公司 | 用于治疗/预防骨骼肌疾病的还原型烟酰胺核糖核苷 |
| EP3980026B1 (en) * | 2019-06-05 | 2024-07-31 | Société des Produits Nestlé S.A. | Reduced nicotinamide ribosides for treating or preventing kidney disease |
| CN110973260A (zh) * | 2019-12-11 | 2020-04-10 | 杨力 | 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用 |
| WO2021123245A1 (en) | 2019-12-19 | 2021-06-24 | Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) | Nad-precursors and dietary restriction for treating age-related medical conditions |
| WO2021180732A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions |
| US20230095103A1 (en) * | 2020-03-09 | 2023-03-30 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of lung diseases and conditions |
| US20230119002A1 (en) * | 2020-03-09 | 2023-04-20 | Societe Des Produits Nestle S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions |
| WO2021180741A1 (en) * | 2020-03-09 | 2021-09-16 | Société des Produits Nestlé S.A. | Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions |
| CN114561342B (zh) * | 2020-11-27 | 2024-12-20 | 西安交通大学医学院第一附属医院 | Nad信号通路激动剂在体外胚胎培养中的应用 |
| CN115669929A (zh) * | 2021-01-15 | 2023-02-03 | 江苏恒正合生命科学有限公司 | 辅助改善记忆的功能性食品其制备方法 |
| US20240245714A1 (en) * | 2021-05-05 | 2024-07-25 | Societe Des Produits Nestle S.A. | Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+) |
| CN117545488A (zh) | 2021-05-27 | 2024-02-09 | 麦德龙国际生物科技有限责任公司 | 烟酸单核苷酸及其酯的结晶固体以及其制作和使用方法 |
| JP2024523126A (ja) * | 2021-06-18 | 2024-06-28 | ミトパワー エルエルシー | Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置 |
| JP7111878B1 (ja) | 2021-10-27 | 2022-08-02 | 旭化成ファーマ株式会社 | ニコチンアミドモノヌクレオチドの製造方法 |
| US20240415862A1 (en) * | 2021-10-27 | 2024-12-19 | Elysium Health Inc. | Methods for treatment of menopausal syndromes |
| WO2023150072A1 (en) | 2022-02-01 | 2023-08-10 | Sinclair David A | Compositions and methods for the preservation of plant matter |
| WO2023150667A2 (en) * | 2022-02-04 | 2023-08-10 | Elysium Health Inc. | Ribose linkers and conjugates thereof |
| WO2024118503A1 (en) | 2022-11-28 | 2024-06-06 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7022680B2 (en) * | 2002-05-30 | 2006-04-04 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases |
| US7977049B2 (en) | 2002-08-09 | 2011-07-12 | President And Fellows Of Harvard College | Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| US7927859B2 (en) * | 2003-08-22 | 2011-04-19 | Rice University | High molar succinate yield bacteria by increasing the intracellular NADH availability |
| CA2555675A1 (en) | 2004-02-10 | 2005-08-25 | Trustees Of Dartmouth College | Nicotinamide riboside kinase compositions and methods for using the same |
| ES2663226T3 (es) | 2004-06-04 | 2018-04-11 | Washington University | Procedimientos y composiciones para tratar neuropatías |
| CN101360421B (zh) * | 2005-11-18 | 2014-06-18 | 康乃尔研究基金会有限公司 | 烟酰核苷组合物及其使用方法 |
| GB201313465D0 (en) | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
| CN109985056A (zh) * | 2013-10-30 | 2019-07-09 | 可劳迈戴斯有限公司 | 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 |
| JP6559713B2 (ja) | 2014-06-06 | 2019-08-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ | ニコチンアミドリボシド類似体ならびにその医薬組成物および使用 |
| CN111643512A (zh) * | 2015-03-16 | 2020-09-11 | 可劳迈戴斯有限公司 | 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途 |
| US10392414B2 (en) | 2015-07-15 | 2019-08-27 | Cornell University | Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives |
| EA035664B1 (ru) | 2015-08-05 | 2020-07-23 | МЕТРО ИНТЕРНЭШНЛ БАЙОТЕК, ЭлЭлСи | Производные никотинамидмононуклеотида и их применение для лечения заболевания или расстройства, связанного с биосинтезом над+ |
| EP3442527B1 (en) * | 2016-04-14 | 2024-06-26 | Chromadex Inc. | Use of nicotinamide riboside in infant formula |
-
2017
- 2017-04-20 AU AU2017254657A patent/AU2017254657A1/en not_active Abandoned
- 2017-04-20 ES ES17786649T patent/ES2948968T3/es active Active
- 2017-04-20 NZ NZ747693A patent/NZ747693A/en unknown
- 2017-04-20 JP JP2018554765A patent/JP7089480B2/ja active Active
- 2017-04-20 MX MX2018012849A patent/MX393076B/es unknown
- 2017-04-20 CN CN201780038245.5A patent/CN109640984A/zh active Pending
- 2017-04-20 CA CA3021571A patent/CA3021571C/en active Active
- 2017-04-20 WO PCT/US2017/028673 patent/WO2017184885A1/en not_active Ceased
- 2017-04-20 KR KR1020187033413A patent/KR20190008246A/ko not_active Ceased
- 2017-04-20 US US15/492,952 patent/US10183036B2/en active Active
- 2017-04-20 EP EP17786649.8A patent/EP3445359B8/en active Active
- 2017-04-20 BR BR112018071573-5A patent/BR112018071573A2/pt not_active Application Discontinuation
-
2018
- 2018-11-16 ZA ZA2018/07736A patent/ZA201807736B/en unknown
-
2021
- 2021-07-16 JP JP2021117648A patent/JP2021176871A/ja active Pending
-
2022
- 2022-08-22 AU AU2022221384A patent/AU2022221384C1/en active Active
- 2022-10-19 JP JP2022167877A patent/JP7493007B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7089480B2 (ja) | 2022-06-22 |
| AU2022221384C1 (en) | 2023-08-03 |
| AU2017254657A1 (en) | 2018-11-15 |
| CA3021571C (en) | 2023-01-03 |
| KR20190008246A (ko) | 2019-01-23 |
| AU2022221384A1 (en) | 2022-09-22 |
| US20170304338A1 (en) | 2017-10-26 |
| JP2019514874A (ja) | 2019-06-06 |
| EP3445359B8 (en) | 2023-09-06 |
| BR112018071573A2 (pt) | 2019-02-12 |
| AU2022221384B2 (en) | 2023-03-23 |
| US10183036B2 (en) | 2019-01-22 |
| CA3021571A1 (en) | 2017-10-26 |
| EP3445359C0 (en) | 2023-06-07 |
| CN109640984A (zh) | 2019-04-16 |
| JP2023002685A (ja) | 2023-01-10 |
| MX2018012849A (es) | 2019-08-29 |
| EP3445359A4 (en) | 2019-12-25 |
| JP7493007B2 (ja) | 2024-05-30 |
| ZA201807736B (en) | 2020-05-27 |
| EP3445359A1 (en) | 2019-02-27 |
| JP2021176871A (ja) | 2021-11-11 |
| ES2948968T3 (es) | 2023-09-22 |
| WO2017184885A8 (en) | 2023-08-24 |
| NZ747693A (en) | 2023-07-28 |
| WO2017184885A1 (en) | 2017-10-26 |
| EP3445359B1 (en) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393076B (es) | Uso de derivados de ribósido de ácido nicotínico o ribósido de nicotinamida, y derivados reducidos de estos, como precursores que incrementan nad+ | |
| BR112017019696A2 (pt) | composto e usos de um composto | |
| EA201890435A1 (ru) | Производные никотинамидмононуклеотида и их применение | |
| WO2020131578A3 (en) | Nicotinyl riboside compounds and their uses | |
| MX2021009652A (es) | Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. | |
| BR112012020742A2 (pt) | derivados de pirazolo piperidina como inibidores de nadph oxidase. | |
| BR112012030818A2 (pt) | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" | |
| PH12014501134B1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MX2012000414A (es) | Derivados piridin-4-ilo. | |
| PH12016501567B1 (en) | 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
| BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
| MX361652B (es) | Análogos de cortistatina y síntesis y usos de los mismos. | |
| CR20130210A (es) | DERIVADOS DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA COMO INHIBIDORES DE JAK | |
| BR112014002245A2 (pt) | derivados de piridin-2(1h)-ona como inibidores de jak | |
| DK2007429T3 (da) | Oralt præparat med gavnlige cardiovaskulære virkninger indeholdende berberin | |
| UY31305A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| AU2017356887A8 (en) | sGC stimulators | |
| UY31839A (es) | Compuestos | |
| MX2012007896A (es) | Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica. | |
| BR112016005509A8 (pt) | método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica | |
| UY34009A (es) | ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?. | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| BR112018004244A2 (pt) | formulações sólidas de pirofosfato férrico solúvel, kits e seus métodos de uso | |
| PH12015501643B1 (en) | Methods of use of phenoxypropylamine compounds to treat depression | |
| GEP20196957B (en) | Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations |